Tacitus Therapeutics is a clinical-stage biotechnology company developing advanced medicines for
treatment of blood cancers, immune disorders and other intractable disease conditions. Our mission is
to pioneer best-in-class therapies using proprietary cell expansion, differentiation and engineering
platform technologies that overcome the limitations of traditional cell transplantation. Initial targets
include a lead clinical program (HSC100) investigating the treatment of blood cancers, followed by
preclinical programs to address clotting disorders and other serious unmet medical needs.